Emergent BioSolutions Inc. (EBS): Operating Cash Flow
$170.60M
Year ended 2025-12-31
$97.70M
Trailing 12 months to 2026-06-30
-20.5%
5-year compound annual growth
+14.9%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $170.60M | +190.6% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $58.70M | n/m | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | -$206.30M | n/m | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | -$34.10M | n/m | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | $320.20M | -40.4% | 2024-03-08, From 2021-01-01 |
| 2020-12-31 | $536.90M | +185.6% | 2023-12-11, From 2020-01-01 |
| 2019-12-31 | $188.00M | +349.8% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $41.80M | -79.9% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $208.10M | +281.1% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $54.60M | +28.4% | 2019-02-22, From 2016-01-01 |
| 2015-12-31 | $42.52M | -62.1% | 2018-02-23, From 2015-01-01 |
| 2014-12-31 | $112.32M | +15.8% | 2015-03-09, From 2014-01-01 |
| 2013-12-31 | $96.97M | +144.6% | 2015-03-09, From 2013-01-01 |
| 2012-12-31 | $39.64M | +225.3% | 2015-03-09, From 2012-01-01 |
| 2011-12-31 | $12.19M | -87.6% | 2014-03-10, From 2011-01-01 |
| 2010-12-31 | $98.02M | +228.2% | 2013-03-08, From 2010-01-01 |
| 2009-12-31 | $29.87M | n/a | 2012-03-09, From 2009-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $170.60M | +190.6% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $151.99M | -19.7% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $142.00M | -28.4% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $156.12M | -26.8% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $47.33M | -72.5% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $329.32M | +60.7% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $137.99M | +437.1% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$466.00M | n/m |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $179.55M | n/m |
Compare EBS, PCRX, CORT, AMPH side by side · Screen every company in Pharmaceutical Preparations ↗